RecruitingNot applicableNCT06005181
12
studies recruiting now
as of 7 Sept 2026
67
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
23 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT06847165
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
RecruitingPhase 2NCT04395196
RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure
RecruitingNot applicableNCT07547696
CARRII Native Intervention Optimization Trial
RecruitingNot applicableNCT07016009
Thrive Person-Centered Planning Program for Young Adults With Fetal Alcohol Spectrum Disorders
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Fetal alcohol syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Fetal alcohol syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
16 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Gabapentin (Gabapentin)
Phase 2/3Alcohol (Ablysinol)
Phase 2/3Cycloserine (Seromycin)
Phase 2Memantine
Phase 2Varenicline
Phase 2Nicotine (Habitrol)
Phase 2Saracatinib
Phase 2Rimonabant (Acomplia)
+ 8 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).